Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial

202314 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: The Lancet Infectious Diseases

Volume 24, Issue 1, pp. 25-35

Field-Weighted Citation Impact: 3.66